Loading
A phase 2 trial of HRS-7058 in pancreatic ductal adenocarcinoma, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer is a phase 2 interventional study registered as NCT07589569 by Shandong Suncadia Medicine Co., Ltd., with 92 participants planned, started 2026-06-04 and due to reach its primary completion in 2028-12. Interventions recorded: HRS-7058.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.